Chemours Co. (NYSE:CC) shares were up 8.5% during trading on Tuesday . The stock traded as high as $9.63 and last traded at $9.54, with a volume of 3,266,583 shares traded. The stock had previously closed at $8.79.

Several research analysts recently issued reports on CC shares. Zacks Investment Research lowered shares of Chemours from a “hold” rating to a “sell” rating in a research note on Monday, April 4th. Jefferies Group reiterated a “hold” rating on shares of Chemours in a research note on Wednesday, April 13th. Citigroup Inc. increased their price target on shares of Chemours from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Monday, April 18th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Chemours in a research note on Wednesday, May 4th. Finally, Barclays PLC increased their price target on shares of Chemours from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, May 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $10.13.

The stock’s market capitalization is $1.69 billion. The firm’s 50 day moving average price is $8.54 and its 200-day moving average price is $7.22.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, May 2nd. The company reported $0.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.04. The business earned $1.30 billion during the quarter, compared to analysts’ expectations of $1.27 billion. The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.33 earnings per share. Equities research analysts predict that Chemours Co. will post $0.71 earnings per share for the current year.

In other Chemours news, CFO Mark Newman purchased 2,800 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The shares were purchased at an average cost of $9.71 per share, for a total transaction of $27,188.00. Following the completion of the purchase, the chief financial officer now directly owns 108,533 shares in the company, valued at $1,053,855.43. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bradley J. Bell purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 4th. The stock was acquired at an average price of $9.65 per share, for a total transaction of $96,500.00. Following the completion of the purchase, the director now owns 21,747 shares of the company’s stock, valued at $209,858.55. The disclosure for this purchase can be found here.

Several hedge funds have bought and sold shares of CC. State of New Jersey Common Pension Fund D increased its stake in Chemours by 1,700.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 900,000 shares of the company’s stock worth $4,824,000 after buying an additional 850,000 shares during the period. First Trust Advisors LP acquired a new stake in Chemours during the fourth quarter worth $4,266,000. Cornerstone Capital Management Holdings LLC. increased its stake in Chemours by 54.0% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 277,881 shares of the company’s stock worth $1,489,000 after buying an additional 97,430 shares during the period. State of Wisconsin Investment Board increased its stake in Chemours by 6.8% in the fourth quarter. State of Wisconsin Investment Board now owns 402,390 shares of the company’s stock worth $2,157,000 after buying an additional 25,620 shares during the period. Finally, Brown Advisory Inc. increased its stake in Chemours by 9.1% in the fourth quarter. Brown Advisory Inc. now owns 246,270 shares of the company’s stock worth $1,320,000 after buying an additional 20,561 shares during the period.

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Company’s Titanium Technologies segment manufactures titanium dioxide (TiO2), which is a pigment used to deliver whiteness, opacity, brightness and protection from sunlight in applications, such as architectural and industrial coatings, plastic packaging, polyvinyl chloride (PVC) window profiles, laminate papers, coated paper and coated paperboard used for packaging.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.